Cargando…
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who took nirmatrelvir/ritonavir and 250 who did not....
Autores principales: | Congdon, Seth, Narrowe, Zev, Yone, Nang, Gunn, Jacob, Deng, Yuting, Nori, Priya, Cowman, Kelsie, Islam, Marjan, Rikin, Sharon, Starrels, Joanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640584/ https://www.ncbi.nlm.nih.gov/pubmed/37951998 http://dx.doi.org/10.1038/s41598-023-46912-4 |
Ejemplares similares
-
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022) -
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)